
Sign up to save your podcasts
Or


In this episode of the Bendy Bodies podcast, Dr. Linda Bluestein, the Hypermobility MD, has an in-depth conversation with Dr. Clair Francomano, a leading expert on connective tissue disorders and Chair of the Medical and Scientific Advisory Board for the Ehlers-Danlos Society. Dr. Francomano shares her insights on diagnosing hypermobile Ehlers-Danlos Syndrome (hEDS) versus hypermobility spectrum disorders (HSD), the current state of genetic testing, and emerging biomarkers (are we close?) that could revolutionize hEDS diagnosis. She discusses the potential connections between EDS, mast cell activation syndrome (MCAS), and postural orthostatic tachycardia syndrome (POTS), offering advice for patients navigating this complex landscape. With updates from ongoing research, this episode is essential listening for those with EDS or related conditions.
Takeaways:
Differences Between hEDS and HSD: Dr. Francomano explains the nuanced distinctions between hypermobile EDS (hEDS) and hypermobility spectrum disorders (HSD), noting that these categories may overlap more than previously thought and might benefit from unified diagnostic criteria in the future.
Genetic Testing Red Flags: While genetic testing can be useful, Dr. Francomano highlights specific “red flags” in family history or personal health that should prompt a referral to a geneticist for further investigation.
Current Limitations of Genetic Testing for hEDS: Unlike other types of EDS, hEDS currently has no identified genetic markers, meaning diagnosis relies on clinical criteria rather than genetic testing alone.
Emerging Biomarkers Show Promise: New studies, such as those exploring fibronectin and calocrine, suggest potential biomarkers for hEDS and HSD, which could transform diagnosis and treatment in the future.
Holistic Approach to Comorbidities: Dr. Francomano discusses how hEDS often presents with comorbidities like POTS and mast cell activation syndrome, recommending a comprehensive, multidisciplinary approach to manage these interconnected symptoms effectively.
Connect with YOUR Bendy Specialist, Dr. Linda Bluestein, MD at https://www.hypermobilitymd.com/.
Thank YOU so much for tuning in. We hope you found this episode informative, inspiring, useful, validating, and enjoyable. Join us on the next episode for YOUR time to level up your knowledge about hypermobility disorders and the people who have them.
Join YOUR Bendy Bodies community at https://www.bendybodiespodcast.com/.
Learn more about Human Content at http://www.human-content.com
Podcast Advertising/Business Inquiries: [email protected]
YOUR bendy body is our highest priority!
Learn about Dr. Clair Francomano
Her Book: https://amzn.to/4e3eSaF
Instagram: @dr.clairfrancomano
Youtube: @DoctorClair
Red Flags List: https://www.bendybodiespodcast.com/p/redflags/
Keep up to date with the HypermobilityMD:
YouTube: youtube.com/@bendybodiespodcast
Twitter: twitter.com/BluesteinLinda
LinkedIn: linkedin.com/in/hypermobilitymd
Facebook: facebook.com/BendyBodiesPodcast
Blog: hypermobilitymd.com/blog
Part of the Human Content Podcast Network
Learn more about your ad choices. Visit megaphone.fm/adchoices
By Dr. Linda Bluestein4.9
210210 ratings
In this episode of the Bendy Bodies podcast, Dr. Linda Bluestein, the Hypermobility MD, has an in-depth conversation with Dr. Clair Francomano, a leading expert on connective tissue disorders and Chair of the Medical and Scientific Advisory Board for the Ehlers-Danlos Society. Dr. Francomano shares her insights on diagnosing hypermobile Ehlers-Danlos Syndrome (hEDS) versus hypermobility spectrum disorders (HSD), the current state of genetic testing, and emerging biomarkers (are we close?) that could revolutionize hEDS diagnosis. She discusses the potential connections between EDS, mast cell activation syndrome (MCAS), and postural orthostatic tachycardia syndrome (POTS), offering advice for patients navigating this complex landscape. With updates from ongoing research, this episode is essential listening for those with EDS or related conditions.
Takeaways:
Differences Between hEDS and HSD: Dr. Francomano explains the nuanced distinctions between hypermobile EDS (hEDS) and hypermobility spectrum disorders (HSD), noting that these categories may overlap more than previously thought and might benefit from unified diagnostic criteria in the future.
Genetic Testing Red Flags: While genetic testing can be useful, Dr. Francomano highlights specific “red flags” in family history or personal health that should prompt a referral to a geneticist for further investigation.
Current Limitations of Genetic Testing for hEDS: Unlike other types of EDS, hEDS currently has no identified genetic markers, meaning diagnosis relies on clinical criteria rather than genetic testing alone.
Emerging Biomarkers Show Promise: New studies, such as those exploring fibronectin and calocrine, suggest potential biomarkers for hEDS and HSD, which could transform diagnosis and treatment in the future.
Holistic Approach to Comorbidities: Dr. Francomano discusses how hEDS often presents with comorbidities like POTS and mast cell activation syndrome, recommending a comprehensive, multidisciplinary approach to manage these interconnected symptoms effectively.
Connect with YOUR Bendy Specialist, Dr. Linda Bluestein, MD at https://www.hypermobilitymd.com/.
Thank YOU so much for tuning in. We hope you found this episode informative, inspiring, useful, validating, and enjoyable. Join us on the next episode for YOUR time to level up your knowledge about hypermobility disorders and the people who have them.
Join YOUR Bendy Bodies community at https://www.bendybodiespodcast.com/.
Learn more about Human Content at http://www.human-content.com
Podcast Advertising/Business Inquiries: [email protected]
YOUR bendy body is our highest priority!
Learn about Dr. Clair Francomano
Her Book: https://amzn.to/4e3eSaF
Instagram: @dr.clairfrancomano
Youtube: @DoctorClair
Red Flags List: https://www.bendybodiespodcast.com/p/redflags/
Keep up to date with the HypermobilityMD:
YouTube: youtube.com/@bendybodiespodcast
Twitter: twitter.com/BluesteinLinda
LinkedIn: linkedin.com/in/hypermobilitymd
Facebook: facebook.com/BendyBodiesPodcast
Blog: hypermobilitymd.com/blog
Part of the Human Content Podcast Network
Learn more about your ad choices. Visit megaphone.fm/adchoices

772 Listeners

1,338 Listeners

177 Listeners

3,360 Listeners

9,232 Listeners

1,110 Listeners

351 Listeners

1,503 Listeners

308 Listeners

560 Listeners

232 Listeners

470 Listeners

116 Listeners

112 Listeners

43 Listeners

189 Listeners

258 Listeners

20 Listeners

23 Listeners

46 Listeners

13 Listeners

83 Listeners

82 Listeners

5 Listeners

122 Listeners

4 Listeners

13 Listeners

937 Listeners